Products for Research Use Only

Tebentafusp

CAT: 0804-HY-P99339-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99339-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen) . Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells[1][2].
CAS Number
1874157-95-5
Product Name Alternative
IMCgp100
UNSPSC
12352203
Target
Interleukin Related; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tebentafusp.html
Purity
99.90
Solubility
10 mM in DMSO
Smiles
[Tebentafusp]
Molecular Weight
(76.16 kDa)
References & Citations
[1]Middleton MR, et al. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clin Cancer Res. 2020 Nov 15;26 (22) :5869-5878. |[2]Dhillon S. Tebentafusp: First Approval. Drugs. 2022 Apr;82 (6) :703-710. |[3]Boudousquie C, et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells. Immunology. 2017 Nov;152 (3) :425-438. |[4]Baeuerle P A, et al. Passive immunotherapy by T cell–engaging bispecifi c antibodies[M]//Cancer Vaccines. CRC Press, 2015: 266-278.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched